Biohit Oyj’s Optio Schemes I 2013 and II 2013
Biohit Oyj June 20, 2013 at 12 noon local time (EET)
On the basis of authorization given by General Shareholders’ Meeting of 13.4.2011 Biohit Oyj’s Board of Directors has on 19th June 2013 decided on two option schemes. Option rights are distributed to company’s management and employees to strengthen their commitment and enhance their motivation. In addition option rights are distributed to Mikko Salaspuro and Martti Marvola on the basis of strengthening their commitment to product development performed for the Company and intellectual property rights received by the company and existing contractual obligations of the company that are waived by the recipients of the option rights in connection of the receipt of the option rights.
Option rights in scheme I 2013 are marked as I 2013A, I 2013B, I 2013C, I 2013D and I 2013E. The Board shall have the right to convert option rights possessed by the Company or its group of companies from a one option class to another option class and also to decide on the re-granting of option rights that have been restored to the company. The maximum total number of the option rights to be granted is 500.000 option rights. 200.00 option rights will be offered to Managing Director Semi Korpela and the remaining 300.000 option right will be offered to company management and employees later. Each option right entitles its holder to subscribe one new B-share in the company. For option right class I 2013A share subscription period commences on 1 June 2014, for option right class I 2013B on 1 June 2015, for option right class I 2013C on 1 June 2016, for option right class I 2013D on 1 June 2017 and for option right class I 2013E on 1 June 2018. For all option rights the share subscription period ends on 31 May 2019. Share subscription price is 3.00 euros. The subscription price can also be amended pursuant to terms and conditions of the option scheme.
Option rights in scheme II 2013 are marked as II 2013. 320.000 option rights are granted to Mikko Salaspuro and 100.000 option rights are granted to Martti Marvola. Each option right entitles its holder to subscribe one new B-share in the company. For option rights II 2013 share subscription period commences on 1 July 2013 and ends on 30 June 2015. Share subscription price is 3,00 euros. The subscription price can also be amended pursuant to terms and conditions of the option scheme.
The terms and conditions of the option schemes are in full enclosed and also available on Biohit Oyj’s home pages: www.biohithealthcare.com/investors/corporate-governance
Biohit Oyj
Board of Directors
Appendix: Terms of Biohit Oyj’s Option Schemes I 2013 and II 2013
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission is "Innovating for Health". The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit's Series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector. www.biohithealthcare.com.